In turn, the gain in lumbar spine BMD after Ronacaleret treatment was significantly below the increase seen with rhPTH or alendronate. Moreover, total hip BMD was even slightly decreased Testosterone Propionate info 12 months of treatment with Ronacaleret, compared with the increase seen with rhPTH or alendronate (32). These disappointing results have led to the interruption of the clinical development of this compound for osteoporosis treatment. However, more studies are needed to determine its clinical usefulness (33). Besides the need for an appropriate pharmacokinetic profile, additional challenges exist with the use of calcilytics. First, the therapeutic window between the desired effects on bone and the unwanted hypercalcemia is quite small. Second, off-target effects limit the usefulness of Testosterone Propionate info because CaSR are also expressed in other organs besides the parathyroid glands, including kidney, Test Propionate, brain, and endothelial cells.